Twas the week before Christmas and the good news was flowing for clinical stage biotech Neurizon Therapeutics (ASX:NUZ), ...
Highlights: IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase ...
Pending FDA clearance of the IND application, Neurizon said it anticipated Massachusetts General Hospital filing a protocol ...
Percheron Therapuetic's key trial for Duchenne muscular dystrophy has flopped, sending the shares into freefall ...
Pharmaust Limited (AU:NUZ) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...
Neurizon Therapeutics has reported a positive interim eight-month update on its ongoing 12-month open-label extension (OLE) ...
Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, NUZ-001. Amyotrophic Lateral Sclerosis (ALS) is a fatal type of motor ...
Neurizon Therapeutics Limited , a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead ...
These innovative studies reveal NUZ-001’s unique mechanism of action in preventing the aggregation of TAR DNA-binding protein 43 (TDP-43), a key pathological feature of ALS, and the ability of NUZ-001 ...